2026-05-08T17:33:38Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/203692024-09-21T13:42:03Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Ng, Melissa S F author Kwok, Immanuel author Tan, Leonard author Shi, Changming author Cerezo-Wallis, Daniela author Tan, Yingrou author Leong, Keith author Calvo, Gabriel F author Yang, Katharine author Zhang, Yuning author Jin, Jingsi author Liong, Ka Hang author Wu, Dandan author He, Rui author Liu, Dehua author Teh, Ye Chean author Bleriot, Camille author Caronni, Nicoletta author Liu, Zhaoyuan author Duan, Kaibo author Narang, Vipin author Ballesteros, Iván author Moalli, Federica author Li, Mengwei author Chen, Jinmiao author Liu, Yao author Liu, Lianxin author Qi, Jingjing author Liu, Yingbin author Jiang, Lingxi author Shen, Baiyong author Cheng, Hui author Cheng, Tao author Angeli, Veronique author Sharma, Ankur author Loh, Yuin-Han author Tey, Hong Liang author Chong, Shu Zhen author Iannacone, Matteo author Ostuni, Renato author Hidalgo, Andrés author Ginhoux, Florent author Ng, Lai Guan author 2024-01-12 Neutrophils are increasingly recognized as key players in the tumor immune response and are associated with poor clinical outcomes. Despite recent advances characterizing the diversity of neutrophil states in cancer, common trajectories and mechanisms governing the ontogeny and relationship between these neutrophil states remain undefined. Here, we demonstrate that immature and mature neutrophils that enter tumors undergo irreversible epigenetic, transcriptional, and proteomic modifications to converge into a distinct, terminally differentiated dcTRAIL-R1+ state. Reprogrammed dcTRAIL-R1+ neutrophils predominantly localize to a glycolytic and hypoxic niche at the tumor core and exert pro-angiogenic function that favors tumor growth. We found similar trajectories in neutrophils across multiple tumor types and in humans, suggesting that targeting this program may provide a means of enhancing certain cancer immunotherapies. Science. 2024 Jan 12;383(6679):eadf6493. 10.1126/science.adf6493 1095-9203 Science (New York, N.Y.) 38207030 http://hdl.handle.net/20.500.12105/20369 Deterministic reprogramming of neutrophils within tumors.